In this phase II study, sepranolone 10 mg administered subcutaneously during the late luteal phase reduced PMDD symptoms more than placebo.
Some, but not all, studies suggest that PMDD is a risk factor for postpartum depression.
In a recent meta-analysis, Yan and colleagues looked at the prevalence of suicidal ideation among women diagnosed with PMDD.
In an evidence-based review published in 2012, Laura Wakil, Samantha Meltzer-Brody, and Susan Girdler present a thorough review of premenstrual dysphoric disorder (PMDD), reviewing its diagnosis and treatment options.
There is excellent data to support the use of selective serotonin and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs) for the treatment of premenstrual dysphoric disorder (PMDD); however, many women do not want to take [...]
Not infrequently we see women who ask about the possibility of oophorectomy (surgical removal of the ovaries) as a means of managing what appears to be a menstrually related mood disorder. While this is an [...]
Brexanolone, to be marketed by Sage Therapeutics as Zulresso, was initially approved in March 2019, as a treatment for postpartum depression. At that time, we were told that Zulresso would be available in June 2019. [...]
Chasteberry, the fruit of the chaste tree or Vitex agnus castus, has long been touted as a remedy for a range of reproductive problems, including premenstrual symptoms or PMS. Two recent publications have reviewed data [...]